Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso

Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso

Chronic organizing pneumonia (COP) has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arhritis, but the association of COP and dermatomyositis (DM) has rarely been documented. We report a 55 year-old woman with well-documented DM and a COP. She was...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yáñez V,Jorge, Cisternas M,Marcela, Saldías H,Velia, Saldías P,Fernando
Lenguaje:Spanish / Castilian
Publicado: Sociedad Médica de Santiago 2009
Materias:
Dermatomyositis
Pneumonia
Rituximab
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100013
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0034-98872009000100013
record_format dspace
spelling oai:scielo:S0034-988720090001000132009-04-13Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un casoYáñez V,JorgeCisternas M,MarcelaSaldías H,VeliaSaldías P,Fernando Dermatomyositis Pneumonia Rituximab Chronic organizing pneumonia (COP) has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arhritis, but the association of COP and dermatomyositis (DM) has rarely been documented. We report a 55 year-old woman with well-documented DM and a COP. She was refractory to steroids and two other immunosuppressive agents therapy (cyclophosphamide and azathioprine). Therefore, rituximab (2 x 1 g infusions) was used for treatment. During the following weeks her strength gradually increased while creatine kinase (CK), C reactive protein and erythrocyte sedimentation rate normalized. After 6 months, she had a relapse with increased muscle enzymes, fever and modérate muscle weakness. After a second course of rituximab (2 x 1 g infusions), the patient demonstrated a remarkable clinical response as indicated by an increase in muscle strength and moderate decline in creatine kinase levels. Lung abnormalities resolved significantly on high resolution chest CT sean. Thus, B-cell depletion therapy with rituximab used alone or in combination with other immunosuppressants may be a viable option in patients with polymyositis-dermatomyositis and pneumonia refractory to current therapies.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.137 n.1 20092009-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100013es10.4067/S0034-98872009000100013
institution Scielo Chile
collection Scielo Chile
language Spanish / Castilian
topic Dermatomyositis
Pneumonia
Rituximab
spellingShingle Dermatomyositis
Pneumonia
Rituximab
Yáñez V,Jorge
Cisternas M,Marcela
Saldías H,Velia
Saldías P,Fernando
Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso
description Chronic organizing pneumonia (COP) has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arhritis, but the association of COP and dermatomyositis (DM) has rarely been documented. We report a 55 year-old woman with well-documented DM and a COP. She was refractory to steroids and two other immunosuppressive agents therapy (cyclophosphamide and azathioprine). Therefore, rituximab (2 x 1 g infusions) was used for treatment. During the following weeks her strength gradually increased while creatine kinase (CK), C reactive protein and erythrocyte sedimentation rate normalized. After 6 months, she had a relapse with increased muscle enzymes, fever and modérate muscle weakness. After a second course of rituximab (2 x 1 g infusions), the patient demonstrated a remarkable clinical response as indicated by an increase in muscle strength and moderate decline in creatine kinase levels. Lung abnormalities resolved significantly on high resolution chest CT sean. Thus, B-cell depletion therapy with rituximab used alone or in combination with other immunosuppressants may be a viable option in patients with polymyositis-dermatomyositis and pneumonia refractory to current therapies.
author Yáñez V,Jorge
Cisternas M,Marcela
Saldías H,Velia
Saldías P,Fernando
author_facet Yáñez V,Jorge
Cisternas M,Marcela
Saldías H,Velia
Saldías P,Fernando
author_sort Yáñez V,Jorge
title Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso
title_short Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso
title_full Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso
title_fullStr Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso
title_full_unstemmed Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un caso
title_sort dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: reporte de un caso
publisher Sociedad Médica de Santiago
publishDate 2009
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100013
work_keys_str_mv AT yanezvjorge dermatomiositisrefractariaasociadaaneumoniaenorganizaciontratadaconrituximabreportedeuncaso
AT cisternasmmarcela dermatomiositisrefractariaasociadaaneumoniaenorganizaciontratadaconrituximabreportedeuncaso
AT saldiashvelia dermatomiositisrefractariaasociadaaneumoniaenorganizaciontratadaconrituximabreportedeuncaso
AT saldiaspfernando dermatomiositisrefractariaasociadaaneumoniaenorganizaciontratadaconrituximabreportedeuncaso
_version_ 1718436422123257856

Ejemplares similares